Incorporate the most translatable 3D in vitro models available into your oncology drug development programs. We exclusively provide preclinical oncology drug development and validation services using unique organoid models developed using IP-protected Hubrecht Organoid Technology (HUB) protocols, as well as HUB’s biobank of already established patient-derived organoids (PDO).
Our organoid services include:
Choose from a rapidly expanding collection of patient-derived HUB organoids covering breast, colorectal, and pancreatic cancer from HUB’s established biobank.
HUB’s adult stem cell-derived organoids are developed from patient tumor as well as healthy tissue, using highly refined, proprietary culture methods originally developed in the Clevers Lab. Organoids developed using HUB’s protocols faithfully recapitulate original patient tissue histo- and molecular pathology and show high predictivity of patient response for your drug development studies.
Gain access to an expanded repertoire of cancer indications, mutational, and pharmacological profiles through PDX-derived organoids (PDXO), developed using HUB protocols.
Robust and reproducible PDXO models are generated from our extensive collection of well-characterized PDX. Matched in vitro PDXO and in vivo PDX model pairs provide a unique preclinical workflow with improved predictivity and a more rapid and informed study transition to accelerate your drug discovery programs.
Our ever expanding collection of organoids are accessed, searched, and selected through our newly launched organoid database OrganoidBase collating light microscopy, genomic, transcriptomic, and pharmacology data.